CS236674B2 - Manufacturing method of calcareous salt of oxaprozine - Google Patents

Manufacturing method of calcareous salt of oxaprozine Download PDF

Info

Publication number
CS236674B2
CS236674B2 CS823052A CS305282A CS236674B2 CS 236674 B2 CS236674 B2 CS 236674B2 CS 823052 A CS823052 A CS 823052A CS 305282 A CS305282 A CS 305282A CS 236674 B2 CS236674 B2 CS 236674B2
Authority
CS
Czechoslovakia
Prior art keywords
oxaprozin
calcium
salt
sodium
tablet
Prior art date
Application number
CS823052A
Other languages
Czech (cs)
English (en)
Inventor
Ahmed Saeed Mughal
Original Assignee
Wyeth John & Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth John & Brother Ltd filed Critical Wyeth John & Brother Ltd
Publication of CS236674B2 publication Critical patent/CS236674B2/cs

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CS823052A 1981-04-28 1982-04-28 Manufacturing method of calcareous salt of oxaprozine CS236674B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8113074 1981-04-28

Publications (1)

Publication Number Publication Date
CS236674B2 true CS236674B2 (en) 1985-05-15

Family

ID=10521427

Family Applications (1)

Application Number Title Priority Date Filing Date
CS823052A CS236674B2 (en) 1981-04-28 1982-04-28 Manufacturing method of calcareous salt of oxaprozine

Country Status (24)

Country Link
US (2) US4465838A (es)
EP (1) EP0063884B1 (es)
JP (1) JPS57181072A (es)
KR (1) KR880000871B1 (es)
AT (1) ATE14015T1 (es)
AU (1) AU544975B2 (es)
CA (1) CA1169867A (es)
CS (1) CS236674B2 (es)
DD (1) DD202017A5 (es)
DE (1) DE3264400D1 (es)
DK (1) DK150604C (es)
ES (1) ES511730A0 (es)
FI (1) FI71314C (es)
GR (1) GR75913B (es)
HU (1) HU185276B (es)
IE (1) IE52909B1 (es)
IL (1) IL65443A (es)
MY (1) MY8700599A (es)
NZ (1) NZ200247A (es)
PH (1) PH18053A (es)
PL (1) PL136322B1 (es)
PT (1) PT74794B (es)
ZA (1) ZA822355B (es)
ZW (1) ZW7482A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US6726928B2 (en) * 1994-10-28 2004-04-27 R.P. Scherer Technologies, Inc. Process for preparing solid dosage forms for unpalatable pharmaceuticals
CN1129429C (zh) * 1996-05-20 2003-12-03 G·D·瑟尔公司 钾、钠和三羟甲基氨基甲烷噁丙嗪盐药物配方
US7358254B2 (en) * 2001-07-13 2008-04-15 Bristol-Myers Squibb Company Method for treating atherosclerosis employing an aP2 inhibitor and combination
AU2006228869A1 (en) * 2005-03-30 2006-10-05 Astion Pharma A/S Oxaprozin or a closely related compound for the treatment of eczema
AR054336A1 (es) * 2005-03-30 2007-06-20 Astion Dev As Tratamiento de enfermedades dermatologicas y del prurito
EP2340296B1 (en) * 2008-08-26 2014-10-08 Dorf Ketal Chemicals (I) Private Limited A new additive for inhibiting acid corrosion and method of using the new additive
KR20140065862A (ko) * 2012-11-22 2014-05-30 에스케이케미칼주식회사 발포성 속붕해성 이매티닙 제제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1206403A (en) * 1966-12-15 1970-09-23 Wyeth John & Brother Ltd Oxazoles
GB1245087A (en) * 1967-10-26 1971-09-02 Wyeth John & Brother Ltd Heterocyclic compounds
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles

Also Published As

Publication number Publication date
ZA822355B (en) 1983-11-30
IL65443A (en) 1985-04-30
ES8307230A1 (es) 1983-07-01
AU8237882A (en) 1982-11-04
ZW7482A1 (en) 1983-11-09
IE52909B1 (en) 1988-04-13
FI71314B (fi) 1986-09-09
IL65443A0 (en) 1982-07-30
DK150604B (da) 1987-04-13
DE3264400D1 (en) 1985-08-01
PT74794A (en) 1982-05-01
ES511730A0 (es) 1983-07-01
US4465838A (en) 1984-08-14
MY8700599A (en) 1987-12-31
GR75913B (es) 1984-08-02
FI71314C (fi) 1986-12-19
HU185276B (en) 1984-12-28
FI821324L (fi) 1982-10-29
PL236145A1 (es) 1982-12-06
DK183582A (da) 1982-10-29
US4532253A (en) 1985-07-30
JPS57181072A (en) 1982-11-08
IE820766L (en) 1982-10-28
KR830009772A (ko) 1983-12-23
PT74794B (en) 1983-11-07
NZ200247A (en) 1984-10-19
FI821324A0 (fi) 1982-04-15
EP0063884A1 (en) 1982-11-03
DK150604C (da) 1987-12-07
AU544975B2 (en) 1985-06-27
ATE14015T1 (de) 1985-07-15
JPH0261466B2 (es) 1990-12-20
PH18053A (en) 1985-03-18
KR880000871B1 (ko) 1988-05-28
EP0063884B1 (en) 1985-06-26
CA1169867A (en) 1984-06-26
PL136322B1 (en) 1986-02-28
DD202017A5 (de) 1983-08-24

Similar Documents

Publication Publication Date Title
DE60128683T2 (de) Stabilisierte pharmazeutische zusammenstellungen die den calziumkanalblocker azelnidipine enthalten
SA94150373A (ar) صياغات جديدة واستخدام صياغة في علاج و/أوالوقاية من اضطرابات معينة
RU2004123624A (ru) Сухие гранулированные композиции азитромицина
EA002331B1 (ru) Фармацевтический препарат, содержащий клодронат в качестве активного ингредиента и агрегат микрокристаллической целлюлозы и диоксида кремния в качестве наполнителя
CA2083683C (en) Stable formulation of analapril salt, a process for the preparation thereof and the use thereof
KR920006909B1 (ko) 니트렌디핀을 함유하는 고상 약제의 제조 방법
CS236674B2 (en) Manufacturing method of calcareous salt of oxaprozine
KR20010071765A (ko) 제약학적 레보타이록신 제제
US4666919A (en) Stabilized pharmaceutical composition containing an isocarbostyril derivative
EP0380021B1 (en) Stabilizing system for solid dosage forms
SK106094A3 (en) Pharmaceutical agent
DE3517820A1 (de) Pharmazeutische praeparate mit antihypertensiver und kardioprotektiver wirkung
EP1292303B1 (en) A stable pharmaceutical formulation comprising torsemide modification ii
EP1292598B1 (en) Process for drying amoxicillin
US2768115A (en) Penicillin-aspirin tablets
DE3922441A1 (de) Ibuprofen- und s-(+)-ibuprofen-zubereitungen und verfahren zu ihrer herstellung
EP1407766B1 (en) Pharmaceutical compositions that contain a salt of alendronic acid
GB2097389A (en) Oxazole derivative
PL196046B1 (pl) Postać krystaliczna monohydratu cytrynianu (2S,3S)-N-(2-metoksy-5-t-butylofenylo)metylo-2-difenylometylo-1-azabicyklo[2.2.2]oktano-3-aminy, środek farmaceutyczny, zastosowanie tej postaci krystalicznej i sposób wytwarzania tej postaci krystalicznej
JPH0469126B2 (es)
US3993778A (en) Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use
GB2148894A (en) Aluminium salts of oxazole derivatives
JPS61200942A (ja) ビタミンK↓2−ジメチル−β−シクロデキストリン包接化合物
JP2001064159A (ja) 複合顆粒剤
TW202227047A (zh) 甲狀腺荷爾蒙的製劑化方法